Replies to post #1819 on BioPharmX Corp fka BPMX

[Whos_Who]

I don't see the company moving forward with P3 until partnership or the approval of the shares and R/S. We should already be in P3! Plain and simple, they don't have the funds. Too much time has gone by for a good (IOI) not to have been presented to the board. Why they haven't moved forward with the non-dilutive partnership route just baffles me. Is Anja and the board looking to go forward without partnership and fund P3 through offerings? Has greed set in? Are they waiting for a release of information that could start moving the share price higher? I know Anja stated that they were working on new undisclosed products. Are those the delay?

Everything is coming down to the wire. Many emails from BioPharmX have stated that there will be an announcement before the end of this quarter in regards to partnership/funding P3. Many longs are watching with concerned eyes.

Why are we in the twenties? Investors want to know how we're funding the next phase Anja! Pick an IOI!! Lock in a deal that's best for shareholders!

https://www.axial.net/forum/what-expect-indication-interest/

From a buyer's prospective
http://jimsteinsharpe.com/searching/making-the-offer/

[Whos_Who]

"Then, why have they signaled doing an RS if needed again, if the next offering is assumed to be positive and above SP? "

Maybe the board hasn't signed a deal because they wanted to get to August and the annual shareholders meeting to put this share increase and R/S deal out there as a feeler. As the votes pour in, especially from the institutional investors, I believe that will be the influence of their overall decision on whether to partner up or not.

I sure would love to know where we stand in the vote count at this time. I believe that's the biggest factor here now.